IntoCell Inc
KOSDAQ:287840
Decide a qué precio te sentirías cómodo comprando y te ayudaremos a estar preparado.
|
I
|
IntoCell Inc
KOSDAQ:287840
|
KR |
|
S
|
Sektkellerei J Oppmann AG
XMUN:1SK
|
DE |
|
R
|
RAMM Pharma Corp
CNSX:RAMM
|
CA |
|
Taiwan Tea Corp
TWSE:2913
|
TW |
|
Quilter PLC
F:2FQ0
|
UK |
Valor intrínseco
No hay suficientes datos para calcular de forma fiable el valor intrínseco de IntoCell Inc.
¿Nuestras valoraciones funcionan de verdad? Ver resultados del backtest .
Análisis fundamental
Qué hace IntoCell
IntoCell, Inc. engages in the research and development of ADC platform technology. The company is headquartered in Daejeon, Daejeon and currently employs 43 full-time employees. The company went IPO on 2025-05-23. The firm mainly develops ortho-hydroxy-protected aryl sulfate (OHPAS) platform technology, which is a linker connecting to drugs. In addition, the Company also develops platform technologies such as payload modification technology (PMT) platform technology, which reduces drug uptake into normal cells, and proprietary drug technology used in ADC development.
- Sede central
- Corea KR
- Empleados
- 43
- Fecha de salida a bolsa
- 23 may., 2025